Rick Fair has a 20-year track record as a strategist and commercial leader in the biopharmaceutical industry. He joined Bellicum as President and CEO in January 2017 from Genentech/Roche where he most recently served as Senior Vice President, Head of Oncology Global Product Strategy, leading oncology product strategy and global commercialization. In this role, he oversaw the global launch of five new molecular entities, including TECENTRIQ®, the first immunotherapy approval for patients with advanced bladder cancer, and numerous line extensions. He also contributed to a substantial expansion of investment into cancer immunotherapy and precision medicine. Previously, he held several commercial leadership positions within Genentech, including franchise leadership with P&L responsibility for its thrombolytics and oral oncolytics businesses. Prior to Genentech, Mr. Fair spent nine years in the pharmaceutical business at Johnson & Johnson, holding leadership roles in marketing, managed care and reimbursement strategy, and managed care customer management. Mr. Fair received his B.S. from the University of Michigan and his M.B.A. from Columbia Business School.